In a reshaped strategy, OssDsign has accelerated its efforts to establish Catalyst in the US spinal fusion market, and will allocate additional capital to sales and marketing and R&D, which we argue is a natural decision given that more than 90% of the spine orthobiologics market remains untapped. The recent PROPEL data, including an 88.4% fusion rate in a highly complex patient cohort, suggests Catalyst is worth investing in.

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.

Läs mer på SEB Research